Many patients who stop taking it tend to gain back weight or lose the health benefits they had achieved
Similar content being viewed by others Background Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are modified derivatives of glucagon-like peptide 1 (GLP-1) that simulate the regulatory effect of GLP-1 on blood glucose levels
At the cellular level, GLP-1 can significantly increase the expression levels of ABCA1 and ABCG1, and decrease the level of intracellular cholesterol, which inhibits the transformation of macrophages into foam cells [72]
GLP-1 medications can be expensive, especially for those without consistent insurance coverage
Also, the inclusion of the drugs in public drug formularies and expanded insurance coverage for chronic condition management escalates accessibility, especially for underserved populations, and is driving the demand and growth of the market
This is the single most useful data point for deciding when to stay at a dose
02105-1/asset/8468e457-0c7f-4e4c-9b6d-2202dbefa9cb/main.assets/gr1_lrg.jpg)
